Meeting Coverage
ECTRIMS
European Committee for Treatment and Research in Multiple Sclerosis
Is "therapeutic inertia" to blame?
Latest ECTRIMS Meeting Coverage
Starting monoclonal antibody therapy during childhood reduced long-term disability
Liver toxicity may still be a concern
Patients with high NfL at disease onset may benefit from high-efficacy treatments
Analysis looks at pooled data of 17,000 MS trial participants
Ozanimod led to test score improvements in interim analysis
Subgroup analysis shows brain penetration
NfL changes occurred in advance of, not coincident with, clinical worsening
MS field faces immense opportunity to move beyond disease suppression, keynote speaker says
Both provided rapid B-cell depletion
CD40 ligand inhibitor leads to sustained reduction of MRI disease activity
DELIVER-MS shows racial and ethnic diversity in clinical trials can be improved
Rituximab did not show non-inferiority in comparative effectiveness study
ARISE trial investigates radiologically isolated syndrome
Disability, relapses no better than disease-modifying drug